45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis

ABFM Family Medicine Certification Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Exam Structure, Blueprint & Clinical Decision-Making

1.1 Exam Blueprint, FMCLA vs. One-Day Exam & Board Scoring 1.2 Clinical Reasoning, Test-Taking Strategy & Ambiguity Management 1.3 Evidence-Based Medicine & Clinical Practice Guidelines in Primary Care

2 Chapter 2: Healthcare Systems, Practice Management & Quality

2.1 Practice Management, Billing, Coding & Documentation 2.2 Quality Improvement, Patient Safety & Diagnostic Stewardship 2.3 Interprofessional Team-Based Care & Care Coordination

3 Chapter 3: Ethics, Law, Biostatistics & Health Equity

3.1 Medical Ethics, Informed Consent & Surrogate Decision-Making 3.2 Biostatistics, Clinical Epidemiology & Diagnostic Test Interpretation 3.3 Social Determinants of Health, Health Equity & Cultural Humility 3.4 Physician Wellness, Burnout Prevention & Professionalism

4 Chapter 4: Lifestyle Counseling & Behavior Change

4.1 Alcohol Use Screening & Brief Intervention 4.2 Illicit Drug & Cannabis Counseling 4.3 Tobacco & Vaping Cessation Counseling

5 Chapter 5: Nutrition, Physical Activity & Chronic Disease Prevention

5.1 Dietary Counseling for Obesity & Chronic Disease Prevention 5.2 Exercise Prescription & Physical Activity Counseling 5.3 Genetic Risk Assessment & Family History Counseling

6 Chapter 6: Routine Adult Immunizations

6.1 ACIP Adult Respiratory Vaccines: Influenza, COVID-19, RSV & Pneumococcal 6.2 ACIP Adult Non-Respiratory Vaccines: Tdap, Shingrix, HPV & Hep B 6.3 Immunizations in Special Populations: Pregnancy, Asplenia & Immunocompromise

7 Chapter 7: Pediatric Health Maintenance & Surveillance

7.1 Newborn Examination & Early Postnatal Care 7.2 Well-Child Care, Developmental Surveillance & Milestones 7.3 Pediatric & Adolescent Screening: Vision, Hearing, Anemia & Lead 7.4 Pediatric Oral Health, Dental Screening & Fluoride

8 Chapter 8: Behavioral Health & Safety Screening

8.1 Primary Care Depression, Anxiety & Behavioral Health Screening 8.2 Domestic Violence, Intimate Partner Violence & Firearm Safety 8.3 Occupational Health & Recreational Safety Counseling

9 Chapter 9: Adult Preventive Screening: Cardiovascular & Metabolic

9.1 Cardiovascular Disease & Hypertension Screening 9.2 Type 2 Diabetes Screening & Prediabetes Risk Stratification 9.3 Abdominal Aortic Aneurysm & Osteoporosis Screening

10 Chapter 10: Adult Cancer Screening: Breast & Gynecologic

10.1 Breast Cancer Screening & Risk-Assessment 10.2 Cervical Cancer Screening & ASCCP Algorithms 10.3 Skin Cancer Clinical Assessment & Counseling

11 Chapter 11: Adult Cancer Screening: Colorectal, Lung & Prostate

11.1 Colorectal Cancer Screening Modalities & Intervals 11.2 Lung Cancer Screening with Low-Dose CT 11.3 Prostate Cancer Screening & Shared Decision-Making

12 Chapter 12: Sexual Health, Infectious Disease Screening & Contraception

12.1 Sexual Health Counseling & Risk-Reduction Strategies 12.2 STI Screening: Chlamydia, Gonorrhea, Syphilis & Trichomoniasis 12.3 Bloodborne Infectious Disease Screening: HIV & Hepatitis C

13 Chapter 13: Reproductive Life Planning, Lactation & Preoperative Care

13.1 Preconception Planning & Comprehensive Contraception Management 13.2 Lactation Support & Breastfeeding Counseling 13.3 Preoperative Medical Evaluation & Pre-Participation Sports Exam

14 Chapter 14: Emergent Cardiovascular Conditions

14.1 Acute Coronary Syndromes & Myocardial Infarction 14.2 Acute Chest Pain Risk Stratification & Triage 14.3 Acute or Critical Valvular Heart Emergencies

15 Chapter 15: Cardiac Arrhythmias, Heart Failure & Hypertensive Crises

15.1 Acute Atrial & Ventricular Arrhythmias 15.2 Acute Decompensated Heart Failure & Cardiogenic Shock 15.3 Hypertensive Emergency & Urgency Management

16 Chapter 16: Vascular & Thromboembolic Emergencies

16.1 Pulmonary Embolism & Deep Vein Thrombosis 16.2 Acute Aortic Syndromes & Peripheral Vascular Emergencies 16.3 Critical Limb Ischemia & Acute Arterial Occlusion

17 Chapter 17: Neurologic Emergencies: Stroke & Altered Consciousness

17.1 Acute Ischemic Stroke & Intracranial Hemorrhage 17.2 Syncope Evaluation & Status Epilepticus 17.3 Acute Delirium, Encephalopathy & Severe Confusion

18 Chapter 18: Neurologic Trauma & Acute Cranial Emergencies

18.1 Concussion, Moderate-to-Severe TBI & Intracranial Injury 18.2 Thunderclap & Acute Severe Secondary Headaches 18.3 Acute Ophthalmologic Emergencies

19 Chapter 19: Acute Abdominal, Pelvic & Gastrointestinal Emergencies

19.1 Acute Abdominal & Pelvic Pain Triage 19.2 Upper & Lower Gastrointestinal Bleeding 19.3 Acute Hepatic Failure, Cholangitis & Severe Jaundice

20 Chapter 20: Acute Pulmonary & Airway Emergencies

20.1 Acute Hypoxic Respiratory Failure & ARDS 20.2 Severe Community-Acquired Pneumonia & Empyema 20.3 Acute Severe Epistaxis & Airway Obstruction

21 Chapter 21: Acute Traumatic Injuries & Wound Care

21.1 Major Trauma Resuscitation & Initial Assessment 21.2 Burn Assessment, Inhalation Injury & Resuscitation 21.3 Laceration Management, Complex Wounds & Animal Bites

22 Chapter 22: Acute Orthopedic & Musculoskeletal Emergencies

22.1 Acute Ambulatory Fractures & Initial Splinting 22.2 Compartment Syndrome & Major Orthopedic Trauma 22.3 Septic Arthritis & Acute Microcrystalline Crises

23 Chapter 23: Severe Infections, Sepsis & Systemic Emergencies

23.1 Sepsis, Septic Shock & Initial Fluid Resuscitation 23.2 Necrotizing Soft Tissue Infections & Severe CNS Infections 23.3 Anaphylaxis Diagnosis, Epinephrine Dosing & Airway Protection

24 Chapter 24: Metabolic, Endocrine & Electrolyte Emergencies

24.1 Diabetic Ketoacidosis & Hyperosmolar Hyperglycemic State 24.2 Critical Electrolyte Emergencies: Dyskalemias & Dysnatremias 24.3 Severe Calcium Abnormalities & Acute Adrenal Crisis

25 Chapter 25: Hematologic, Urologic & Dental Emergencies

25.1 Severe Symptomatic Anemias & Coagulopathic Emergencies 25.2 Testicular Torsion, Priapism & Acute Urinary Retention 25.3 Urgent Odontogenic Infections & Dental Trauma

26 Chapter 26: Psychiatric, Behavioral & Obstetric/Gynecologic Emergencies

26.1 Suicidal Ideation, Acute Agitation & Behavioral Emergencies 26.2 Acute Physical & Sexual Assault Care 26.3 Life-Threatening Vaginal Bleeding & Ectopic Pregnancy 26.4 Environmental Heat Stroke & Severe Hypothermia

27 Chapter 27: Acute Head, Neck & Neurologic Symptoms

27.1 Primary Acute Headaches: Migraine, Tension & Cluster 27.2 Concussion & Minor Closed Head Injury Evaluation 27.3 Transient Ischemic Attack Evaluation & ABCD2 Risk Scoring

28 Chapter 28: Acute Cranial Nerves, Hearing & Sensory Symptoms

28.1 Peripheral Neuropathies: Bell's Palsy, Carpal Tunnel & Radiculopathy 28.2 Acute Tinnitus, Sudden Sensorineural Hearing Loss & Cerumen Impaction 28.3 Acute Dizziness, Benign Paroxysmal Positional Vertigo & Vestibular Neuritis

29 Chapter 29: Acute Upper Respiratory Tract Infections

29.1 Acute Viral Rhinosinusitis vs. Bacterial Rhinosinusitis 29.2 Acute Pharyngitis: Group A Streptococcus & Centor Criteria 29.3 Acute Otitis Media, Otitis Externa & Serous Effusion

30 Chapter 30: Acute Lower Respiratory Infections & Cough

30.1 Influenza, COVID-19 & Viral Respiratory Syndromes 30.2 Acute Bronchitis & Lower Respiratory Tract Infections 30.3 Ambulatory Community-Acquired Pneumonia

31 Chapter 31: Allergic, Nasal & Non-Infectious Pulmonary Conditions

31.1 Allergic Rhinitis & Acute Non-Anaphylactic Allergic Reactions 31.2 Acute Dyspnea in Ambulatory Care 31.3 Interstitial Lung Diseases & Sarcoidosis Presentation

32 Chapter 32: Acute Chest, Cardiac & Vascular Symptoms

32.1 Palpitations Evaluation & Arrhythmia Triage in Primary Care 32.2 Deep Vein Thrombosis & Superficial Thrombophlebitis 32.3 Ambulatory Hypotension & Orthostasis Evaluation

33 Chapter 33: Acute Upper Gastrointestinal Conditions

33.1 Peptic Ulcer Disease & Gastritis 33.2 Dysphagia, Esophagitis & Acute Esophageal Disorders 33.3 Acute Nausea, Vomiting & Foodborne Illness

34 Chapter 34: Acute Lower Gastrointestinal Conditions

34.1 Acute Infectious Diarrhea & Gastroenteritis 34.2 Acute Constipation & Functional Bowel Changes 34.3 Ano-Rectal Disorders: Hemorrhoids, Fissures, Abscesses & Pruritus Ani

35 Chapter 35: Inflammatory, Functional & Malabsorptive GI Disorders

35.1 Acute Flares of Inflammatory Bowel Disease 35.2 Irritable Bowel Syndrome: Diagnosis, Subtyping & Management 35.3 Celiac Disease & Malabsorption Syndromes

36 Chapter 36: Acute Abdominal, Hepatic & Biliary Disorders

36.1 Ambulatory Abdominal & Pelvic Pain Triage 36.2 Acute Cholecystitis, Biliary Colic & Pancreatitis 36.3 Acute Liver Injury & Viral Hepatitis

37 Chapter 37: Acute Abdominal Wall, Hernias & Dental Conditions

37.1 Abdominal Wall, Inguinal & Ventral Hernias 37.2 Acute Dental Pain, Odontogenic Abscess & Aphthous Ulcers 37.3 Acute Edema: Unilateral vs. Bilateral Diagnostic Evaluation

38 Chapter 38: Acute Infectious Dermatoses

38.1 Bacterial Skin Infections: Impetigo, Cellulitis & Cutaneous Abscesses 38.2 Fungal Skin Infections: Tinea Corporis, Cruris, Pedis & Onychomycosis 38.3 Viral Cutaneous Infections: Herpes Simplex, Zoster & Molluscum Contagiosum

39 Chapter 39: Inflammatory, Allergic & Autoimmune Dermatoses

39.1 Atopic Dermatitis, Contact Dermatitis & Eczematous Flares 39.2 Non-Infectious Rashes: Urticaria, Drug Eruptions & Erythema Multiforme 39.3 Cutaneous Malignancies & Premalignant Lesions: AK, BCC, SCC & Melanoma

40 Chapter 40: Acute Shoulder, Elbow & Upper Extremity Injuries

40.1 Rotator Cuff Pathology, Tendinopathy & Shoulder Impingement 40.2 Lateral & Medial Epicondylitis, Olecranon Bursitis & Elbow Sprains 40.3 Wrist & Hand Soft-Tissue Injuries: De Quervain, TFCC & Finger Sprains

41 Chapter 41: Acute Knee, Ankle & Lower Extremity Injuries

41.1 Meniscal Tears, Ligamentous Knee Injuries & Patellofemoral Pain 41.2 Ankle Sprains, Ottawa Ankle Rules & Achilles Tendinopathy 41.3 Plantar Fasciitis, Shin Splints & Overuse Syndromes

42 Chapter 42: Acute Ambulatory Fractures & Dislocations

42.1 Distal Radius, Scaphoid & Common Upper Extremity Fractures 42.2 Metatarsal, Clavicle & Common Lower Extremity Fractures 42.3 Joint Dislocation Management: Nursemaid's Elbow & Shoulder Subluxation

43 Chapter 43: Acute Axial Musculoskeletal Pain & Falls

43.1 Acute Low Back Pain: Red Flags, Strain & Disc Herniation 43.2 Acute Cervical Strain, Whiplash & Axial Neck Pain 43.3 Evaluation of Falls in Ambulatory & Older Patients

44 Chapter 44: Acute Inflammatory Arthropathies & Generalized Pain

44.1 Acute Inflammatory Arthritis & Spondyloarthropathies 44.2 Myalgias, Rhabdomyolysis & Post-Viral Pain Syndromes 44.3 Acute Non-Headache Pain Management Strategies

45 Chapter 45: Acute Renal, Urinary & Genitourinary Conditions

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis 45.2 Hematuria Workup & Glomerulonephritis 45.3 Nephrolithiasis & Acute Urinary Tract Obstruction

46 Chapter 46: Acute Male Genitourinary & Prostatic Conditions

46.1 Acute Prostatitis, Epididymitis & Orchitis 46.2 Acute Scrotal Pain: Torsion vs Appendage, BPH & Male Genital Emergencies 46.3 Acute Urinary Retention & Incontinence Evaluation

47 Chapter 47: Acute Women's Health & Early Pregnancy Care

47.1 Early Pregnancy Diagnosis, Dating & Initial Complications 47.2 Abnormal Uterine Bleeding & Acute Menstrual Disorders 47.3 Premenstrual Syndrome & Premenstrual Dysphoric Disorder

48 Chapter 48: Breast Disorders, STIs & Pediatric Elimination

48.1 Palpable Breast Mass, Mastitis & Nipple Discharge 48.2 Sexually Transmitted Infections: Diagnosis, Staging & CDC Guidelines 48.3 Pediatric Enuresis & Encopresis

49 Chapter 49: Systemic Signs, Metabolic Dysregulation & Miscellaneous Infections

49.1 Acute Fever, Sepsis Screening & FUO in Primary Care 49.2 Acute Hyperglycemia & Symptomatic Hypoglycemia 49.3 Electrolyte Abnormalities: Mild-to-Moderate Disturbances 49.4 Vector-Borne, Tick-Borne & Rickettsial Illnesses

50 Chapter 50: Chronic Cardiovascular Diseases: Hypertension & Ischemia

50.1 Essential Hypertension Management: 2025 AHA/ACC Guideline & JNC Strategies 50.2 Chronic Coronary Artery Disease & Post-MI Secondary Prevention 50.3 Chronic Heart Failure: HFrEF, HFpEF & Quadruple GDMT

51 Chapter 51: Chronic Vascular, Valvular & Dyslipidemic Diseases

51.1 Peripheral Arterial Disease & Claudication 51.2 Chronic Valvular Heart Disease & Murmur Evaluation 51.3 Lipid Disorders & ASCVD Risk-Based Statin Therapy

52 Chapter 52: Chronic Respiratory Diseases: Asthma & COPD

52.1 Chronic Asthma Management: GINA Stepwise SMART Therapy 52.2 Chronic Obstructive Pulmonary Disease: GOLD Recommendations 52.3 Solitary Pulmonary Nodule Evaluation & Fleischner Society Criteria

53 Chapter 53: Chronic Metabolic Diseases: Diabetes Mellitus

53.1 Type 2 Diabetes Management: ADA Pharmacotherapy Algorithms 53.2 Type 1 Diabetes: Basal-Bolus Insulin, CGMs & Diabetic Complications 53.3 Diabetic Microvascular & Macrovascular Disease Surveillance

54 Chapter 54: Obesity, Nutrition & Metabolic Bone Diseases

54.1 Medical & Behavioral Management of Obesity & Incretin Mimetics 54.2 Osteoporosis & Metabolic Bone Disease: DEXA, FRAX & Antiresorptives 54.3 Nutritional Deficiencies: Vitamin D, B12, Iron & Malnutrition

55 Chapter 55: Chronic Endocrine Disorders

55.1 Primary & Subclinical Hypothyroidism, Hyperthyroidism & Nodules 55.2 Adrenal Disorders: Addison's Disease & Cushing's Syndrome 55.3 Hypercalcemia, Hyperparathyroidism & Pituitary Disorders

56 Chapter 56: Chronic Kidney Disease & Venous Disorders

56.1 Chronic Kidney Disease: KDIGO Staging & Renoprotective Therapy 56.2 Chronic Venous Insufficiency, Stasis Dermatitis & Lymphedema 56.3 Chronic Electrolyte & Acid-Base Management in CKD

57 Chapter 57: Chronic Gastrointestinal & Hepatic Diseases

57.1 Gastroesophageal Reflux Disease, Barrett's Esophagus & Dyspepsia 57.2 Chronic Liver Disease: MASLD/NAFLD, Cirrhosis & Portal Hypertension 57.3 Viral Hepatitis B & C: Long-Term Monitoring & DAA Therapy

58 Chapter 58: Colorectal Surveillance & Chronic Pancreaticobiliary Care

58.1 Post-Polypectomy Colorectal Polyp Surveillance Guidelines 58.2 Chronic Pancreatitis & Exocrine Pancreatic Insufficiency 58.3 Chronic Nausea, Gastroparesis & Functional GI Disorders

59 Chapter 59: Chronic Musculoskeletal & Rheumatologic Disorders

59.1 Osteoarthritis: Hip, Knee & Hand Management 59.2 Spinal Conditions: Spinal Stenosis, Spondylolisthesis & Compression Fractures 59.3 Chronic Myopathies & Fibromyalgia Syndrome

60 Chapter 60: Chronic Neurologic & Neurodegenerative Disorders

60.1 Dementia: Alzheimer's, Vascular & Lewy Body Disease 60.2 Parkinson's Disease & Essential Tremor 60.3 Epilepsy: Chronic Antiseizure Medications & Post-Stroke Care

61 Chapter 61: Chronic Peripheral Nerves, Pain & Sensory Disorders

61.1 Diabetic & Chronic Peripheral Neuropathies 61.2 Chronic Pain Syndromes & Chronic Daily Headaches 61.3 Chronic Tinnitus, Presbycusis & Persistent Dizziness

62 Chapter 62: Chronic Psychiatric Disorders

62.1 Major Depressive Disorder & Generalized Anxiety Disorder 62.2 Bipolar Disorder: Maintenance Pharmacotherapy & Lithium Monitoring 62.3 Adult & Pediatric Attention-Deficit/Hyperactivity Disorder

63 Chapter 63: Chronic Behavioral Health & Neurodevelopmental Conditions

63.1 Chronic Behavioral Conditions: PTSD, OCD & Somatization 63.2 Autism Spectrum Disorder & Intellectual Disabilities 63.3 Eating Disorders: Anorexia Nervosa, Bulimia & Binge Eating

64 Chapter 64: Chronic Substance Use Disorders & Tobacco Cessation

64.1 Alcohol Use Disorder: Pharmacotherapy & Relapse Prevention 64.2 Opioid & Stimulant Use Disorders: MOUD & Harm Reduction 64.3 Longitudinal Tobacco Cessation Pharmacotherapy

65 Chapter 65: Chronic Dermatologic Conditions

65.1 Acne Vulgaris, Rosacea & Seborrheic Dermatitis 65.2 Chronic Plaque Psoriasis & Biologic Therapies 65.3 Chronic Eczema, Hidradenitis Suppurativa & Cutaneous Lupus

66 Chapter 66: Chronic Reproductive, Infectious & Geriatric Special Care

66.1 Chronic Menstrual Disorders, Infertility & Sexual Dysfunction 66.2 Menopause Management & Hormone Replacement Therapy 66.3 Chronic HIV Infection Management & Primary Care Integration 66.4 Gender-Affirming Primary Care & Hormone Therapy 66.5 Advance Care Planning, Palliative Care & End-of-Life Symptom Control

67 Chapter 67: Continuity Care: Sleep, Fatigue, Cancer, Pregnancy & the Adult Preventive Visit

67.1 Chronic Insomnia & Obstructive Sleep Apnea 67.2 Chronic Malaise, Fatigue & ME/CFS 67.3 Primary Care During Cancer Treatment & Survivorship 67.4 Routine Prenatal Care & Longitudinal Pregnancy Management 67.5 The Periodic Adult Health Examination & Medicare Annual Wellness Visit

45.1 Uncomplicated UTI, Pyelonephritis & Acute Urethritis

Key Takeaways Explain This Topic AI

Acute uncomplicated cystitis is defined as a lower urinary tract infection in an otherwise healthy, non-pregnant, immunocompetent premenopausal female with normal urinary tract anatomy; routine pre-treatment urine cultures are not required in classic presentations.

First-line empiric antimicrobial regimens for acute uncomplicated cystitis per IDSA guidelines are nitrofurantoin monohydrate/macrocrystals (100 mg BID x 5 days; avoid if eGFR <30 mL/min), TMP-SMX (1 DS tablet BID x 3 days; only if local E. coli resistance <20%), and fosfomycin trometamol (3 g single oral dose sachet); fluoroquinolones are strictly second-line and must be avoided due to severe adverse effects and stewardship concerns.

Asymptomatic bacteriuria (ASB) must be screened and treated in only two patient populations: pregnant individuals (to prevent acute pyelonephritis, preterm labor, and low birth weight) and patients undergoing invasive urologic procedures with anticipated mucosal bleeding; treating ASB in diabetic, catheterized, or non-pregnant individuals is counter-therapeutic and causes antimicrobial harm.

Outpatient acute pyelonephritis can be treated with oral ciprofloxacin (500 mg BID x 7 days) or levofloxacin (750 mg daily x 5 days) only if local fluoroquinolone resistance is <10%; if resistance is >=10%, administer an initial parenteral dose of ceftriaxone (1 g) before oral therapy.

Acute urethritis is diagnosed via first-catch urine NAAT (not clean-catch midstream); empiric treatment per CDC guidelines mandates dual coverage with ceftriaxone 500 mg IM single dose (for N. gonorrhoeae) plus oral doxycycline 100 mg BID x 7 days (for C. trachomatis), with prompt expedited partner treatment.

Last updated: September 2026

Epidemiology, Pathogenesis & Classification of Lower Urinary Tract Infections

Urinary tract infections (UTIs) represent one of the most common bacterial infections encountered in outpatient family medicine, accounting for over 10 million ambulatory visits annually in the United States. Nearly 50% to 60% of adult women will experience at least one symptomatic UTI during their lifetime, with 20% to 30% suffering a recurrence within 6 months.

Pathogenesis

The overwhelming majority of urinary tract infections occur via the ascending transurethral route . The female anatomical predisposition is primarily driven by a short urethra (~4 cm compared to ~20 cm in males) situated in close proximity to the warm, moist, bacterial reservoirs of the vagina, perineum, and perianal region.

Uropathogen Colonization : Normal vaginal flora, dominated by hydrogen peroxide-producing Lactobacillus species, maintains an acidic vaginal pH (3.8 to 4.5) that inhibits Enterobacteriaceae colonization. Depletion of lactobacilli—triggered by sexual intercourse, spermicide use (nonoxynol-9), systemic antibiotics, or estrogen deficiency in postmenopausal women—permits uropathogenic Escherichia coli (UPEC) to colonize the introitus and periurethral area.

Urothelial Adherence : UPEC strains possess specialized virulence factors, most notably Type 1 fimbriae (mannose-sensitive adhesins that bind uroplakin receptors on superficial bladder umbrella cells) and P fimbriae (pyelonephritis-associated pilus, which binds glycosphingolipids on renal tubular epithelial cells). Adherence triggers bacterial internalization into bladder epithelial cells, forming intracellular bacterial communities (IBCs) that evade host immune surveillance and antibiotic penetration.

Host Inflammatory Response : Bacterial lipopolysaccharide (LPS) activates urothelial Toll-like receptor 4 (TLR4), triggering an intense local release of interleukin-6 (IL-6) and interleukin-8 (IL-8). IL-8 recruits neutrophils into the urinary space, producing the hallmark microscopic pyuria and sensory symptoms of bladder irritation.

Microbial Etiology

Uropathogenic Escherichia coli (UPEC) : Responsible for 75% to 95% of all acute uncomplicated cystitis cases and >80% of outpatient pyelonephritis.

Staphylococcus saprophyticus : Coagulase-negative, novobiocin-resistant staphylococcus accounting for 5% to 15% of uncomplicated UTIs in sexually active young women; characteristically displays seasonal summertime peaks.

Klebsiella pneumoniae & Proteus mirabilis : Account for 3% to 8% each. Proteus mirabilis produces bacterial urease, predisposing to alkaline urine and struvite calculi.

Enterococcus faecalis & Group B Streptococcus ( Streptococcus agalactiae ) : Account for <5% of uncomplicated cystitis; more commonly isolated in older adults, diabetics, and pregnant patients.

Uncomplicated vs. Complicated Urinary Tract Infection

Accurate clinical triage into uncomplicated versus complicated infection dictates the necessity of diagnostic urine cultures, the selection and duration of antimicrobial therapy, and the threshold for urological imaging. CLINICAL CLASSIFICATION OF URINARY TRACT INFECTIONS

• Category Patient Population Diagnostic & Management Mandate
• ═══════════════════════════════════════════════════════════════════════════════════════════
• Acute • Non-pregnant, immunocompetent • Clinical diagnosis; dipstick suffices
• Uncomplicated premenopausal female • Routine urine culture NOT required
• Cystitis • Anatomically normal urinary tract • 3-5 days of first-line oral agents
• No systemic signs of infection • No imaging indicated

• Complicated • All male patients • Urine culture & susceptibility MANDATORY
• UTI • Pregnant females • Minimum 7 to 14 days of therapy
• Uncontrolled diabetes mellitus • Broadened empiric antimicrobial coverage
• Immunocompromise (HIV, transplant) • Low threshold for renal ultrasound / CT
• Indwelling catheter, stent, or PVR • Rule out obstruction, abscess, or stone
• Anatomical defects (strictures, VUR)
• Renal insufficiency / CKD
• ═══════════════════════════════════════════════════════════════════════════════════════════
• Clinical Presentation of Acute Uncomplicated Cystitis

Patients present with a constellation of classic lower urinary tract symptoms (LUTS):

Dysuria : Sharp, burning urethral pain during or immediately following micturition.

Frequency & Urgency : Compelling, uncontrollable urge to void small volumes of urine.

Suprapubic Pain : Dull, aching pressure or discomfort over the urinary bladder.

Gross Hematuria : Present in up to 30% of acute uncomplicated cystitis presentations ("hemorrhagic cystitis"); does not alter classification or portend worse outcomes in acute young women.

CRITICAL EXAM PEARL : The presence of classic dysuria and frequency in the absence of vaginal discharge or vaginal irritation carries a positive predictive value >90% for acute uncomplicated cystitis. Physical examination reveals suprapubic tenderness to palpation, but normal vital signs, absence of fever, and absence of costovertebral angle (CVA) tenderness .

Urinalysis Interpretation: Leukocyte Esterase, Nitrites & Microscopy

Urinalysis is the primary diagnostic adjunct in ambulatory family medicine. A properly collected clean-catch midstream urine specimen is essential to avoid perineal contamination. URINALYSIS INTERPRETATION IN UTI

• Component Diagnostic Mechanism Clinical Pearls & Pitfalls
• ═══════════════════════════════════════════════════════════════════════════════════════════
• Leukocyte • Detects esterase enzyme released • Sensitivity: 75% to 95%; Specificity: 95%
• Esterase by lysed polymorphonuclear cells • Correlates with pyuria (>=10 WBC/mm3)
• (neutrophils) in urine • False negative: concentrated urine,
• glucosuria, high-dose cephalosporins

• Nitrites • Detects conversion of dietary • Highly specific (>95%), moderate sensitivity
• nitrates to nitrites by bacterial • Positive indicates Enterobacteriaceae
• nitrate reductase enzyme • False negatives: Enterococcus, S. sapro-
• phyticus, Pseudomonas (lack reductase);
• bladder dwell time <4 hours; low dietary
• vegetables; high vitamin C (ascorbate)

• Microscopy • Identifies intact WBCs, RBCs, • Significant pyuria: >5 WBCs/HPF
• bacteria, and epithelial cells • Squamous epithelial cells >5/HPF indicate
• perineal contamination (invalid sample)
• ═══════════════════════════════════════════════════════════════════════════════════════════

When is a Urine Culture Indicated?

In an otherwise healthy, non-pregnant woman presenting with classic symptoms of uncomplicated cystitis, routine urine culture and antimicrobial susceptibility testing are NOT cost-effective and are NOT recommended by IDSA guidelines . Empiric therapy is initiated immediately based on clinical presentation and dipstick confirmation.

Urine culture and susceptibility testing ARE mandatory in the following clinical scenarios:

• Suspected acute pyelonephritis or systemic toxicity
• Complicated UTI (males, pregnancy, diabetes, immunosuppression, indwelling hardware)
• Recurrent UTIs (defined as >=2 distinct episodes in 6 months or >=3 episodes in 12 months)
• Symptoms that fail to resolve or recur within 2 to 4 weeks following antimicrobial completion
• Atypical clinical symptoms or diagnostic ambiguity
• Suspected multi-drug resistant organisms (MDROs) or recent hospitalization/international travel
• IDSA Guideline First-Line Antimicrobial Regimens for Uncomplicated Cystitis

The Infectious Diseases Society of America (IDSA) and European Society of Microbiology and Infectious Diseases (ESCMID) establish three primary first-line empiric antimicrobial regimens for acute uncomplicated cystitis. These agents were explicitly selected for their high clinical efficacy, minimal collateral damage to normal gastrointestinal and vaginal microbiomes, and low rates of resistance. FIRST-LINE EMPIRIC REGIMENS FOR ACUTE UNCOMPLICATED CYSTITIS

• Antimicrobial Agent Dosage & Schedule Duration Key Clinical Considerations
• ═══════════════════════════════════════════════════════════════════════════════════════════
• 1. Nitrofurantoin 100 mg PO BID with meals 5 Days • High bladder concentration;
• monohydrate/ negligible tissue penetration
• macrocrystals • CONTRAINDICATED if eGFR <30 mL/min
• (Macrobid) • Ineffective for pyelonephritis/prostate
• Safe in 2nd/3rd trimester (avoid at term)

• 2. Trimethoprim- 1 Double-Strength (DS) tab 3 Days • Dose: 160 mg TMP / 800 mg SMX
• sulfamethoxazole (160/800 mg) PO BID • Avoid if local E. coli resistance >20%
• (TMP-SMX; Bactrim DS) • Avoid in sulfa allergy, G6PD defect
• Risk of hyperkalemia and SJS

• 3. Fosfomycin 3 g PO single-dose sachet 1 Dose • Dissolve powder in 3-4 oz cold water
• trometamol dissolved in cold water • Excellent compliance; ESBL active
• Lower clinical cure (~75-80%) vs Macrobid
• ═══════════════════════════════════════════════════════════════════════════════════════════
• Detailed Pharmacotherapy Review
• 1. Nitrofurantoin (Macrobid)

Mechanism : Reduced by bacterial flavoproteins to highly reactive electrophilic intermediates that non-specifically attack ribosomal proteins, DNA, RNA, and metabolic enzymes.

Clinical Strengths : Minimal resistance (<3% to 5% among UPEC despite 60 years of clinical use) and negligible impact on bowel flora.

Crucial Pharmacokinetic Limitation : Rapidly cleared and concentrated exclusively in the urinary bladder lumen. It fails to achieve therapeutic parenchymal tissue levels in the renal parenchyma or prostate gland . Consequently, nitrofurantoin is STRICTLY INEFFECTIVE for acute pyelonephritis, renal abscess, or acute bacterial prostatitis .

Renal Cutoff : Historically contraindicated at CrCl <60 mL/min, the 2015 updated Beers Criteria and American Geriatrics Society revised the threshold down to eGFR <30 mL/min . At eGFR <30 mL/min, urinary drug excretion is insufficient to clear bladder bacteriuria, while systemic accumulation increases the risk of peripheral neuropathy and pulmonary toxicity.

2. Trimethoprim-Sulfamethoxazole (TMP-SMX)

Mechanism : Sequential inhibition of bacterial folic acid synthesis (sulfamethoxazole inhibits dihydropteroate synthase; trimethoprim inhibits dihydrofolate reductase).

Resistance Threshold : TMP-SMX remains an outstanding 3-day regimen only if the local community prevalence of E. coli resistance is known to be <20% and the patient has not received TMP-SMX within the preceding 3 months. If local resistance exceeds 20%, an alternative first-line agent must be chosen.

Adverse Effects : Trimethoprim chemically blocks the epithelial sodium channel (ENaC) in the cortical collecting duct (identical to the potassium-sparing diuretic amiloride), frequently causing hyperkalemia , especially in patients taking ACE inhibitors, ARBs, or spironolactone.

3. Fosfomycin Trometamol

Mechanism : Inactivates bacterial enolpyruvate transferase (MurA), permanently blocking the initial committed step in peptidoglycan cell wall biosynthesis.

Indications : Single 3-gram oral sachet. Retains activity against multidrug-resistant pathogens, including extended-spectrum beta-lactamase (ESBL)-producing E. coli . Although single-dose adherence is 100%, randomized trials (e.g., JAMA 2018) demonstrate that clinical and microbiologic cure rates for fosfomycin (75% to 80%) are modestly inferior to 5 days of nitrofurantoin (84% to 90%).

Second-Line Alternative Regimens: Oral Beta-Lactams

When first-line agents cannot be utilized due to allergy, intolerance, or local resistance, oral beta-lactams are appropriate second-line alternatives:

Cephalexin : 500 mg PO BID to QID for 5 to 7 days.

Cefpodoxime : 100 mg PO BID for 5 to 7 days.

Amoxicillin-Clavulanate : 500/125 mg PO BID for 5 to 7 days.

Caution : Beta-lactams demonstrate lower microbiologic eradication rates and higher recurrence rates compared to nitrofurantoin or TMP-SMX, and are associated with a greater incidence of gastrointestinal adverse effects and vaginal candidiasis. Ampicillin or amoxicillin alone should NEVER be used empirically due to worldwide E. coli resistance exceeding 30% to 50%.

Why Fluoroquinolones are AVOIDED for Uncomplicated Cystitis

Historically, ciprofloxacin (250-500 mg BID x 3 days) was heavily prescribed for uncomplicated cystitis. Today, the FDA, IDSA, and AAFP explicitly state that fluoroquinolones should NOT be used as first-line therapy for acute uncomplicated cystitis .

Warning

FDA BLACK BOX WARNING & ANTIMICROBIAL STEWARDSHIP Fluoroquinolones (ciprofloxacin, levofloxacin, moxifloxacin) carry severe, potentially irreversible and disabling black box warnings:

Tendinopathy & Tendon Rupture : Primarily involving the Achilles tendon; risk is amplified in patients aged >60 years and those taking concurrent systemic corticosteroids.

Peripheral Neuropathy : Axonal polyneuropathy that may become permanent.

Central Nervous System Toxicities : Seizures, hallucinations, psychosis, severe anxiety, and delirium.

Aortic Aneurysm & Dissection : Accelerated collagen degradation in the aortic wall.

QT Prolongation & Torsades de Pointes : Cardiac conduction delays.

Clostridioides difficile Colitis : High propensity to disrupt intestinal microbiome.

Fluoroquinolones must be conserved for serious, invasive infections—specifically acute pyelonephritis and complicated prostatitis—where oral alternatives are severely limited.

Symptomatic Relief: Phenazopyridine (Pyridium)

Phenazopyridine is an azo dye that exerts a topical analgesic effect on the urinary tract mucosa (100 to 200 mg PO TID after meals). It provides symptomatic relief of severe dysuria during the initial 24 to 48 hours while antibiotics take effect.

Duration : Restrict to a maximum of 48 hours ; longer therapy masks persistent infection and increases toxicity.

Patient Counseling : Clinicians must proactively warn patients that phenazopyridine causes harmless, bright orange-to-red discoloration of urine that permanently stains clothing and contact lenses.

Adverse Effects : Prolonged use or accumulation in renal impairment can induce hemolytic anemia and methemoglobinemia .

Asymptomatic Bacteriuria (ASB): Strict Evidence-Based Indications

Asymptomatic bacteriuria (ASB) is defined as the presence of >=10^5 colony-forming units (CFU)/mL of a single bacterial species in a clean-catch voided urine specimen in a patient without any signs or symptoms of a urinary tract infection (two consecutive specimens in females, single specimen in males). EVIDENCE-BASED INDICATIONS FOR SCREENING & TREATING ASB

• Clinical Indication Rationale & Recommended Regimen
• ═══════════════════════════════════════════════════════════════════════════════════════════
• 1. Pregnant Individuals • Progesterone-induced ureteral dilation and mechanical

(Screen at 12-16 weeks) uterine compression cause urinary stasis.

• Untreated ASB progresses to acute pyelonephritis in

20% to 30% of pregnancies.

• High risk of preterm labor, low birth weight, sepsis.

• Treat 4-7 days: cephalexin, amox-clav, nitrofurantoin

(avoid nitrofurantoin in 1st trimester & at term).

• Test-of-cure urine culture 1 to 2 weeks post-treatment.

• 2. Urologic Procedures with • Endoscopic instrumentation (e.g., TURP, ureteroscopy)
• Anticipated Mucosal Bleeding disrupts mucosal barrier, causing direct bacteremic

seeding and high rates of life-threatening urosepsis.

• Screen and treat 24 to 48 hours prior to procedure.

• ═══════════════════════════════════════════════════════════════════════════════════════════
• Clinical Populations in Whom ASB MUST NOT Be Treated

In nearly all other populations, asymptomatic bacteriuria represents benign commensal colonization rather than invasive infection. Extensive clinical trials prove that antibiotic eradication in these groups does not decrease symptomatic UTI episodes, does not reduce mortality, does not improve incontinence, but directly triggers C. difficile infection and promotes multidrug-resistant uropathogens.

Do NOT screen or treat ASB in:

• Non-pregnant premenopausal women
• Well-controlled or poorly controlled diabetic patients
• Elderly community-dwelling or nursing home residents (ASB prevalence 25% to 50%)
• Patients with spinal cord injury or neurogenic bladder
• Patients with indwelling Foley catheters or chronic suprapubic tubes (bacteriuria is universal within 30 days)
• Preoperative non-urologic surgical candidates (e.g., prior to total hip or knee arthroplasty)
• Acute Pyelonephritis: Clinical Presentation, Triage & Management

Acute pyelonephritis is an invasive bacterial infection of the renal parenchyma and pelvicalyceal system, typically arising from transurethral ascent of uropathogens from the bladder.

Clinical Presentation & Diagnostic Triad

Patients present with a systemic, toxic illness characterized by:

Flank Pain & Costovertebral Angle (CVA) Tenderness : Unilateral or bilateral dull, throbbing pain elicited by gentle fist percussion over the 12th rib posteriorly.

High Fever & Shaking Chills / Rigors : Temperature characteristically exceeds 38.0°C (100.4°F), often accompanied by tachycardia and diaphoresis.

Systemic Symptoms : Severe nausea, vomiting, anorexia, headache, and general prostration.

Lower Urinary Tract Symptoms : Dysuria, frequency, and urgency are present in 60% to 70% of patients, but may be absent.

Laboratory & Diagnostic Evaluation

Urinalysis & Microscopy : Marked pyuria, positive leukocyte esterase, and nitrites. The presence of White Blood Cell (WBC) Casts on microscopic examination is pathognomonic for renal parenchymal inflammation , confirming upper tract involvement.

Urine Culture & Susceptibility : Mandatory in 100% of suspected pyelonephritis cases.

Blood Cultures : Indicated in all hospitalized patients, immunocompromised hosts, or when hemodynamic instability/sepsis is suspected. Blood cultures are positive in 15% to 20% of pyelonephritis admissions.

Serum Chemistries & CBC : Leukocytosis with significant left shift (neutrophilic bandemia); elevated serum BUN and creatinine reflecting dehydration or acute parenchymal injury.

Outpatient vs. Inpatient Admission Decision-Making ACUTE PYELONEPHRITIS ADMISSION CRITERIA

• Hemodynamic Instability • Septic shock, hypotension (SBP <90 mmHg), sustained tachycardia
• Severe Clinical Toxicity • High persistent fevers (>39°C), rigors, severe prostration
• Intractable Vomiting • Inability to maintain oral hydration or tolerate oral medications
• Obstruction / Calculi • Known or suspected nephrolithiasis, ureteral stricture, hydronephrosis
• Pregnancy • ALL pregnant women with pyelonephritis mandate inpatient IV therapy
• Severe Comorbidities • Immunocompromise (solid organ transplant, neutropenia, advanced HIV)
• Advanced chronic kidney disease (CKD stage 4 or 5)
• Poorly controlled brittle diabetes mellitus
• Social Vulnerability • Lack of home support, cognitive impairment, inability to follow up
• Outpatient Failure • Persistent fevers or clinical deterioration after 48-72 hours of oral therapy
• Outpatient Empiric Antimicrobial Protocols

Outpatient therapy is appropriate for mild-to-moderate pyelonephritis in stable, reliable patients who can tolerate oral fluids.

Oral Fluoroquinolones (First-Line if Community Resistance <10%) :

Ciprofloxacin : 500 mg PO BID for 7 days (or Ciprofloxacin Extended-Release 1000 mg PO daily x 7 days).

Levofloxacin : 750 mg PO daily for 5 days .

If Local Fluoroquinolone Resistance is >=10% or Unknown :

Administer an initial, long-acting parenteral dose in the clinic: Ceftriaxone 1 g IV/IM (or a consolidated aminoglycoside dose, e.g., Gentamicin 5-7 mg/kg IV) followed by oral fluoroquinolone therapy.

Alternative Oral Regimens (When Fluoroquinolones Cannot Be Used) :

Administer Ceftriaxone 1 g IV/IM initial dose , followed by:

Trimethoprim-Sulfamethoxazole (TMP-SMX DS) : 1 tablet PO BID for 14 days (if susceptibility confirmed), OR

Oral Beta-Lactam : Cefpodoxime 200 mg PO BID or Amoxicillin-Clavulanate 875/125 mg PO BID for 10 to 14 days .

Inpatient Parenteral Regimens

Patients requiring hospitalization should be initiated on intravenous therapy immediately:

First-Line IV : Ceftriaxone 1 g to 2 g IV every 24 hours.

Pseudomonas Coverage / Complicated / Sepsis : Cefepime 2 g IV every 8 to 12 hours, OR Piperacillin-Tazobactam 3.375 g to 4.5 g IV every 6 hours, OR Meropenem 1 g IV every 8 hours (if ESBL risk).

Step-Down Therapy : Transition to oral agents once the patient is afebrile and clinically improving for 24 to 48 hours, guided by culture susceptibility results, completing a total 10- to 14-day antimicrobial course.

Acute Urethritis: Gonococcal vs. Non-Gonococcal Urethritis (NGU)

Acute urethritis is an infectious inflammation of the urethral mucosa, predominantly transmitted through sexual contact in adolescents and young adults.

Clinical Distinction: Gonococcal vs. Non-Gonococcal COMPARISON OF ACUTE URETHRITIS ETIOLOGIES

• Feature Gonococcal Urethritis (GU) Non-Gonococcal Urethritis (NGU)
• ═══════════════════════════════════════════════════════════════════════════════════════════
• Pathogen • Neisseria gonorrhoeae • Chlamydia trachomatis (20-40%)
• (Gram-negative diplococcus) • Mycoplasma genitalium (15-25%)
• Trichomonas vaginalis (2-5%)
• Ureaplasma urealyticum, HSV

Incubation Period • Rapid: 2 to 5 days • Indolent: 1 to 3 weeks

• Urethral Discharge • Copious, thick, frankly PURULENT • Scant to moderate, watery, thin,
• (creamy yellow-green) MUCOPURULENT or clear

Dysuria • Severe, sharp, prominent • Mild to moderate; pruritus/tingling

• Microscopy / • Intracellular Gram-negative • Polymorphonuclear leukocytes (>=2-5/OIF)
• Gram Stain diplococci within neutrophils without intracellular diplococci
• ═══════════════════════════════════════════════════════════════════════════════════════════
• Diagnostic Protocol: Nucleic Acid Amplification Testing (NAAT)

First-Catch Urine NAAT : The diagnostic standard of care. Instruct the patient NOT to void for at least 1 to 2 hours prior to collection . Collect the first 20 to 30 mL of the initial voided urine stream .

CRITICAL EXAM PEARL : Do NOT collect a clean-catch midstream urine for urethritis testing! Midstream collection flushes urethral exudate and pathogens into the toilet, generating false-negative NAAT results. The first 20 mL contains the highest concentration of desquamated urethral epithelial cells harboring N. gonorrhoeae and C. trachomatis .

Gram Stain of Urethral Swab : Point-of-care evaluation demonstrating >=2 to 5 WBCs per oil immersion field with intracellular Gram-negative diplococci provides immediate presumptive confirmation of gonococcal infection.

CDC 2021 Sexually Transmitted Infections Treatment Guidelines

Because co-infection between Neisseria gonorrhoeae and Chlamydia trachomatis occurs in up to 20% to 40% of cases, empiric therapy initiated prior to NAAT confirmation must provide dual coverage: CDC 2021 EMPIRIC ANTIMICROBIAL REGIMEN FOR ACUTE URETHRITIS

• Coverage Target Antimicrobial Regimen & Route
• ═══════════════════════════════════════════════════════════════════════════════════════════
• Gonococcal Coverage • CEFTRIAXONE 500 mg IM in a single dose
• (N. gonorrhoeae) (If body weight >=150 kg [300 lbs], administer Ceftriaxone 1 g IM)

PLUS PLUS

• Chlamydial Coverage • DOXYCYCLINE 100 mg PO BID for 7 days
• (C. trachomatis) (First-line preferred agent; superior eradication)
• ═══════════════════════════════════════════════════════════════════════════════════════════
• The Shift Away from Azithromycin

In prior CDC guidelines, Azithromycin 1 g single oral dose was co-first-line. The CDC 2021 guidelines downgraded Azithromycin .

Why Doxycycline is Superior : Doxycycline achieves significantly higher microbiologic cure rates for rectal chlamydia (which frequently coexists asymptomatically in men and women) and prevents selection of macrolide resistance in Mycoplasma genitalium (where resistance rates to azithromycin now exceed 60% to 80%).

Azithromycin Role : Reserved strictly for patients with documented severe doxycycline allergy or in pregnant patients (Azithromycin 1 g PO single dose).

Comprehensive Management & Partner Notification

Sexual Partner Management : All sexual partners within the preceding 60 days must be evaluated and empirically treated. Provide Expedited Partner Therapy (EPT) (prescribing or dispensing therapy directly to the patient to deliver to partners) where legally permitted.

Sexual Abstinence : Patients and their partners must completely abstain from oral, anal, and vaginal sexual intercourse for 7 days following completion of single-dose therapy or until completion of the 7-day doxycycline regimen , and until all symptoms have completely resolved.

Screening for Co-Infections : All patients diagnosed with an STI must be screened for HIV, syphilis (serology), and Hepatitis B/C.

Loading diagram... Clinical Triage and Management Algorithm for Acute Lower vs Upper Urinary & Genitourinary Infections